560 related articles for article (PubMed ID: 25812459)
1. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.
Castagnola E; Caviglia I; Pescetto L; Bagnasco F; Haupt R; Bandettini R
Future Microbiol; 2015; 10(3):357-64. PubMed ID: 25812459
[TBL] [Abstract][Full Text] [Related]
2. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
3. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
4. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols.
Greenberg D; Moser A; Yagupsky P; Peled N; Hofman Y; Kapelushnik J; Leibovitz E
Int J Antimicrob Agents; 2005 Jun; 25(6):469-73. PubMed ID: 15890499
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of cycling empirical antibiotic therapy for febrile neutropenia in pediatric cancer patients.
Teranishi H; Koga Y; Nishio H; Kato W; Ono H; Kanno S; Nakashima K; Takada H
J Infect Chemother; 2017 Jul; 23(7):463-467. PubMed ID: 28527651
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patients.
Kamonrattana R; Sathitsamitphong L; Choeyprasert W; Charoenkwan P; Natesirinilkul R; Fanhchaksai K
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2733-2737. PubMed ID: 31554370
[TBL] [Abstract][Full Text] [Related]
9. Pediatric fever in neutropenia with bacteremia-Pathogen distribution and in vitro antibiotic susceptibility patterns over time in a retrospective single-center cohort study.
Stergiotis M; Ammann RA; Droz S; Koenig C; Agyeman PKA
PLoS One; 2021; 16(2):e0246654. PubMed ID: 33577566
[TBL] [Abstract][Full Text] [Related]
10. Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance.
Lee NH; Kang JM; Lee JW; Huh HJ; Lee NY; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Infect Dis J; 2020 Oct; 39(10):931-936. PubMed ID: 32453199
[TBL] [Abstract][Full Text] [Related]
11. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Rizal AM; Nordiah AJ; Jamal R
Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia.
Marini BL; Hough SM; Gregg KS; Abu-Seir H; Nagel JL
Support Care Cancer; 2015 Aug; 23(8):2287-95. PubMed ID: 25576429
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility surveillance among gram-negative bacilli at a cancer center.
Jacobson K; Rolston K; Elting L; LeBlanc B; Whimbey E; Ho DH
Chemotherapy; 1999; 45(5):325-34. PubMed ID: 10473920
[TBL] [Abstract][Full Text] [Related]
17. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
[TBL] [Abstract][Full Text] [Related]
18. Review of spectrum and sensitivity of bacterial bloodstream isolates in children with malignancy: A retrospective analysis from a single center.
Reddy R; Pathania S; Kapil A; Bakhshi S
Indian J Cancer; 2014; 51(4):425-7. PubMed ID: 26842147
[TBL] [Abstract][Full Text] [Related]
19. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
Paulus S; Dobson S; Rassekh S; Blondel-Hill E
J Pediatr Hematol Oncol; 2009 Apr; 31(4):267-9. PubMed ID: 19346878
[TBL] [Abstract][Full Text] [Related]
20. Bacteria causing bacteremia in pediatric cancer patients presenting with febrile neutropenia--species distribution and susceptibility patterns.
Miedema KG; Winter RH; Ammann RA; Droz S; Spanjaard L; de Bont ES; Kamps WA; van de Wetering MD; Tissing WJ
Support Care Cancer; 2013 Sep; 21(9):2417-26. PubMed ID: 23579946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
